Board of Directors
|Nick Rodgers, Chairman
Mr Rodgers has considerable Board experience in both public and private growth companies, particularly those in the life science sector, as well as a background as a successful corporate financier and investment banker. Mr Rodgers is currently chairman of SEHTA, one of the largest health technology networking organisations in the UK. Prior to this, he was non-executive director and then chairman of fully listed Oxford Biomedica plc, a leading gene-based biopharmaceutical company, from 2004 until 2016. Previously, Mr Rodgers headed up both the Life Science and Corporate Finance department at Evolution Beeson Gregory (now Investec) advising many listed life science companies from 1989 until 2003.
|Neil Clark, Chief Executive Officer
Mr Clark qualified as an accountant with PwC in Cambridge, UK and worked for over ten years on a variety of national and international assignments in audit, corporate finance and consultancy. In 1997, Mr Clark joined CeNeS Pharmaceuticals plc, a venture capital backed private UK biotech company. Following the successful flotation of CeNeS in 1999, he was appointed CFO. In 2005, he became CEO and led the company through to its sale in 2008. Mr Clark then joined Ergomed in January 2009 and was CFO during its IPO in July 2014 until his move to be full time CEO of PrimeVigilance (Ergomed’s successful drug safety business) in January 2016. Mr Clark is a Fellow of the Institute of Chartered Accountants in England and Wales and has a BSc in Bioscience from the University of Nottingham.
|Dr William Love, Founder and Chief Scientific Officer
Dr Love was a senior scientist at Ciba Geigy/Novartis focused on novel drug delivery technologies and involved in the development of the world’s leading eye-care pharmaceutical, Visudyne. In 1997, Dr Love founded Destiny Pharma and he is the co-inventor of the XF drug platform. Dr Love was a founding member of the BEAM Alliance, an EU SME group focused on promoting antimicrobial drug development. He is an expert advisory board member of Global AMR Innovation Fund, appointed by Professor Dame Sally Davies in October 2016. Dr Love is the named inventor in more than 70 patents. He has experience in drug R&D from discovery and lead identification, through pre-clinical development and into Phase 1/2 clinical development in the UK, EU and US.
|Shaun Claydon, Chief Financial Officer and Company Secretary
Mr Claydon is an accomplished corporate financier and qualified Chartered Accountant with over 16 years’ board level experience, including within the biotechnology sector. He has extensive experience of delivering financial and operating results and from 2015 served as CFO of Creabilis, a venture backed clinical stage specialty pharmaceutical company focused on dermatology treatments, during which he led the $150 million sale of the business to Sienna Biopharmaceuticals. From 2009 to 2014 Mr Claydon was CFO and chief operating officer of Orteq Sports Medicine, a medical device company and world leader in the field of biodegradable polymer technologies. Prior to these positions Mr Claydon held a number of senior financial consultancy and corporate finance roles including at PwC, Evolution Beeson Gregory (now Investec) and HSBC Investment Banking.
|Peter Morgan, Non-Executive Director
Mr Morgan’s early career was spent in the pharmaceutical industry, working as a product manager in the UK before moving to become managing director of a Ciba-Geigy (now Novartis) subsidiary in Scandinavia. Mr Morgan was a founding director of Beaufort Group Limited, a business services company which provided support to pharmaceutical companies. From 2007 until 2015, Mr Morgan was a non-executive director of Oncimmune Limited, a cancer diagnostics company which floated on AIM in 2016. Mr Morgan has advised many of the world’s top pharmaceutical companies including Amgen, Bayer, GSK, Novartis, Novo Nordisk, Pfizer and Roche as well as Quintiles, the world’s largest clinical research organisation. He has a BSc from the University of Nottingham and an MBA from London Business School.
|Dr Huaizheng Peng, Non-Executive Director
Dr Peng serves as general manager of International Operations for China Medical System Holdings, a specialty pharmaceutical company listed on the Hong Kong Stock Exchange. He also served as an independent non-executive director of China Medical System Holdings Ltd between 2007 and 2010. Dr Peng was a partner of Northland Bancorp, a private equity firm. Before that, he worked as a head of life sciences and as a director of corporate finance at Seymour Pierce, a London-based investment bank and stockbroker. Earlier in his career Dr Peng was a senior portfolio manager, specialising in global life science and Asian technology investment at Reabourne Technology Investment Management Limited.
|Dr Debra Barker, Non-Executive Director
Dr Barker has worked at Novartis, Roche, GSK (then SmithKline Beecham) and most recently at Polyphor as Chief Medical and Development Officer. Dr Barker is currently on the board of Hutman Diagnostics, a molecular diagnostic company specialising in antimicrobial resistance, and BerGenBio, an oncology company targeting immune-evasive and therapy resistant cancers. At Novartis Dr Barker held several senior roles including Head of Development for Anti-Infectives, Immunology and Transplantation. Dr Barker was also the medical lead for Swiss based anti-infective specialist Polyphor’s highly successful IPO on the SIX Swiss Exchange.